Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

(2020) Chadi G. Abdallah et al.   NEUROPSYCHOPHARMACOLOGY

NMDA receptor partial agonist, d-cycloserine, enhances 10 Hz rTMS-induced motor plasticity, suggesting long-term potentiation (LTP) as underlying mechanism

(2020) Joshua C. Brown et al.   Brain Stimulation

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

(2019) Gihyun Yoon et al.   JAMA Psychiatry

Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine’s Antidepressant Activity

(2019) Tobias Marton et al.   BIOLOGICAL PSYCHIATRY

Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study

(2019) Mu-Hong Chen et al.   NEUROPSYCHOPHARMACOLOGY

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

(2019) Rachel Ochs-Ross et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

(2018) Nolan R. Williams et al.   AMERICAN JOURNAL OF PSYCHIATRY

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

(2018) Maurizio Fava et al.   MOLECULAR PSYCHIATRY

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

(2017) Lily R. Aleksandrova et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

Use of Ketamine in Elderly Patients with Treatment-Resistant Depression

(2017) Carolina Medeiros da Frota Ribeiro et al.   Current Psychiatry Reports

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

(2017) Gerard Sanacora et al.   JAMA Psychiatry

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

(2016) Jaskaran B. Singh et al.   AMERICAN JOURNAL OF PSYCHIATRY

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

(2015) D. Jeffrey Newport et al.   AMERICAN JOURNAL OF PSYCHIATRY

In vivo evidence for neuroplasticity in older adults

(2015) Fábio Henrique de Gobbi Porto et al.   BRAIN RESEARCH BULLETIN

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

(2015) Lisa M Monteggia et al.   CURRENT OPINION IN NEUROBIOLOGY

Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans

(2015) Suresh D. Muthukumaraswamy et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of ketamine infusion in late onset depression, and conversion to treatment response

(2015) Shrikant Srivastava et al.   Indian Journal of Psychiatry

Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression

(2014) Mark J. Niciu et al.   JOURNAL OF CLINICAL PSYCHIATRY

Failed Response to Repeat Intravenous Ketamine Infusions in Geriatric Patients With Major Depressive Disorder

(2014) Sarah M. Szymkowicz et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex

(2013) W. Zhou et al.   EUROPEAN PSYCHIATRY

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

(2013) Paulo R. Shiroma et al.   JOURNAL OF AFFECTIVE DISORDERS

Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression

(2012) Brian R. Cornwell et al.   BIOLOGICAL PSYCHIATRY

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

(2012) James W. Murrough et al.   BIOLOGICAL PSYCHIATRY

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

(2012) Lobna Ibrahim et al.   NEUROPSYCHOPHARMACOLOGY

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

(2009) Sanjay J. Mathew et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies

(2008) Abebaw Fekadu et al.   JOURNAL OF AFFECTIVE DISORDERS

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

(2008) Gerard Sanacora et al.   NATURE REVIEWS DRUG DISCOVERY

Interindividual variability and age-dependency of motor cortical plasticity induced by paired associative stimulation

(2008) J. Florian M. Müller-Dahlhaus et al.   EXPERIMENTAL BRAIN RESEARCH